fda stopping semaglutide π¨ Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these Semaglutide Shortage Ends: Compounded Versions
Description
Brown JC, Pederson RA, Jorpes E, Mutt V

this could be partly due to differences in baseline BMI and age, because patients with T2D enrolled in trials on obesity show, on average, a lower BMI and a higher age than patients without T2D

This discount card can be used to save up to 80% on brand-name and generic medications

Your independent licensed provider will evaluate your health history and may determine that this class of medication is not the right option for you